Showing 1501-1510 of 3545 results for "".
- Practical Dermatology Names Dr. Lisa Swanson Associate Medical Editorhttps://practicaldermatology.com/news/practical-dermatology-names-dr-lisa-swanson-associate-medical-editor/2470863/Elizabeth (Lisa) Swanson, MD, FAAD, has accepted the position of Associate Medical Editor of Practical Dermatology, the journal announced. In this capacity, Dr. Swanson will work closely with Chief Medical Editor Neal Bhatia, MD, FAAD, to provide direction for Practical Dermat
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- Study Explores How Moderate to Severe Hand Eczema Affects Quality of Lifehttps://practicaldermatology.com/news/moderate-severe-hand-eczema-quality-life-challenges-explored/2470762/Even mild hand eczema can significantly impair one's quality of life and mental health, according to a new study. The findings, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, spanned data collected from 2013 to 2020, addressed the outsized impact of hand eczem
- ADapt Study: Lebrikizumab Improves Skin and Quality of Life in ADhttps://practicaldermatology.com/news/study-lebrikizumab-improves-skin-and-quality-life-ad/2470753/Results from the phase 3b ADapt study presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference indicated lebrikizumab (LEB) improved skin clearance, reduced itch, and enhanced quality of life in patients with moderate-to-severe atopic dermatitis (AD) in whom dupilumab (DUPI) was
- Psoriasis Linked with Education, Mood Disorders: Studyhttps://practicaldermatology.com/news/psoriasis-tied-education-and-mood-disorders-study/2468759/A new genetic study has identified six previously unreported loci associated with psoriasis, emphasizing its genetic complexity and links to socioeconomic and mental health factors. The analysis included data from 925,649 individuals across the FinnGen, Estonian Biobank, and UK Biobank, ma
- Early-Onset AD Linked to Higher Rates of Atopic Marchhttps://practicaldermatology.com/news/early-onset-ad-linked-higher-rates-atopic-march/2468704/Early-onset atopic dermatitis (AD) is associated with higher rates of developing atopic march conditions compared to controls, according to new research in the Journal of the American Academy of Dermatology. “Particular attention should be paid towards risk factors and atopic marc
- Study Links Severe AD With Need for Surgery in Glaucoma Patientshttps://practicaldermatology.com/news/study-links-severe-ad-need-surgery-glaucoma-patients/2468562/Patients suffering from both severe atopic dermatitis (AD) and glaucoma are increasingly likely to need surgical intervention for the glaucoma depending on the severity of their AD, according to a new Journal of Glaucoma study. “Association of Atopic Dermatitis and Risk of Glaucoma Surgery
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Atopic Dermatitis Linked to Peripheral Vascular Diseasehttps://practicaldermatology.com/news/atopic-dermatitis-linked-peripheral-vascular-disease/2468444/People with atopic dermatitis (AD) are almost twice as likely to develop peripheral vascular disease (PVD), Yale School of Medicine researchers found in a new study. “Associated between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research Pro